Amariliz Rivera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amariliz Rivera has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Chaoyang Xue
Public Health Research Institute, New Jersey Medical School, Rutgers University
13 shared publications Keyi Wang
Center for Immunity and Inflammation, and Department of Pediatrics, New Jersey Medical School, Rutgers University, Newark, NJ, 07103, United States
10 shared publicationsVanessa Espinosa
Department of Pediatrics and Center for Immunity and Inflammation, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA
7 shared publicationsYina Wang
Public Health Research Institute, and Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ, 07103, United States
6 shared publicationsOrchi Dutta
Center for Immunity and Inflammation, New Jersey Medical School, Rutgers–The State University of New Jersey , Newark, NJ
5 shared publications- Tobias M. Hohl
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
5 shared publications
Latest Publications
- Open Access
Development of an HK-fbp1-based vaccine platform against Cryptococcus neoformans
Cryptococcal meningitis remains a leading cause of death among HIV/AIDS patients, and no antifungal vaccine is available in clinical use. We previously showed that mice immunized with a heat-killed preparation of Cryptococcus neoformans ( Cn ) fbp1 Δ mutant (HK-fbp1) are protected against cryptococcosis and other invasive mycoses, suggesting that HK-fbp1 is an intriguing vaccine candidate for further study. Recent studies have reported that heat-killed wild type H99 (HK-H99) can also offer some protection in other vaccination models. Here we set out to decipher the differential protective capacity of HK-fbp1 versus HK-H99 across multiple conditions. We observed that HK-fbp1 confers superior protection in both prophylactic and therapeutic intranasal immunization settings than HK-H99, which was associated with greater activation of pulmonary CD4⁺ T cells and stronger airway IFN- γ production. In addition, HK-fbp1 preparations were highly stable, retaining full protective efficacy even after 5 years of frozen storage. Mice intranasally immunized with two-dose HK-fbp1 were protected against challenge by up to 10⁶ H99 cells, a 100-fold increase over the commonly used lethal inoculum. Addition of a CpG adjuvant ODN to HK-fbp1 (HK-bp1/ODN) led to a 5-fold reduction of the intranasal vaccine inoculum required for protection, and itssingle-dose intramuscular vaccination induced protection persisted for at least 3 months post vaccination. Together, these findings highlight the robust protective capacity and formulation versatility of HK-fbp1, supporting its further development as a stable, dose-sparing antifungal vaccine candidate. Importance: Vaccines against viral and bacterial infections have had a transformative impact in our fight against infectious diseases. However, there are no fungal vaccines currently approved for clinical use. This study provides a full characterization of a potent whole cell fungal vaccine we recently developed based on heat-killed Cryptococcus neoformans fbp1 Δ mutant (HK-fbp1) and its adjuvanted version. Our data demonstrates that HK-fbp1 and its adjuvanted version have superior protection advantage than heat-killed wild type H99. Importantly, the HK-fbp1 is highly stable with its preparation remained protective potency after years of frozen storage. Including a CpG adjuvant ODN further reduced the antigen requirement in the intranasal route, and provided HK-fbp1 a highly durable protection after single intramuscular vaccination. These clinically relevant attributes of a successful vaccine, including high stability, dose-sparing potential, and durable efficacy following a single dose, strengthen the rationale for developing HK-fbp1 as a versatile whole-cell antifungal platform.
Open AccessDevelopment of an HK-fbp1-based vaccine platform against Cryptococcus neoformans
Cryptococcal meningitis remains a leading cause of death among HIV/AIDS patients, and no antifungal vaccine is available in clinical use. We previously showed that mice immunized with a heat-killed preparation of Cryptococcus neoformans ( Cn ) fbp1 Δ mutant (HK-fbp1) are protected against cryptococcosis and other invasive mycoses, suggesting that HK-fbp1 is an intriguing vaccine candidate for further study. Recent studies have reported that heat-killed wild type H99 (HK-H99) can also offer some protection in other vaccination models. Here we set out to decipher the differential protective capacity of HK-fbp1 versus HK-H99 across multiple conditions. We observed that HK-fbp1 confers superior protection in both prophylactic and therapeutic intranasal immunization settings than HK-H99, which was associated with greater activation of pulmonary CD4⁺ T cells and stronger airway IFN- γ production. In addition, HK-fbp1 preparations were highly stable, retaining full protective efficacy even after 5 years of frozen storage. Mice intranasally immunized with two-dose HK-fbp1 were protected against challenge by up to 10⁶ H99 cells, a 100-fold increase over the commonly used lethal inoculum. Addition of a CpG adjuvant ODN to HK-fbp1 (HK-bp1/ODN) led to a 5-fold reduction of the intranasal vaccine inoculum required for protection, and itssingle-dose intramuscular vaccination induced protection persisted for at least 3 months post vaccination. Together, these findings highlight the robust protective capacity and formulation versatility of HK-fbp1, supporting its further development as a stable, dose-sparing antifungal vaccine candidate. Importance: Vaccines against viral and bacterial infections have had a transformative impact in our fight against infectious diseases. However, there are no fungal vaccines currently approved for clinical use. This study provides a full characterization of a potent whole cell fungal vaccine we recently developed based on heat-killed Cryptococcus neoformans fbp1 Δ mutant (HK-fbp1) and its adjuvanted version. Our data demonstrates that HK-fbp1 and its adjuvanted version have superior protection advantage than heat-killed wild type H99. Importantly, the HK-fbp1 is highly stable with its preparation remained protective potency after years of frozen storage. Including a CpG adjuvant ODN further reduced the antigen requirement in the intranasal route, and provided HK-fbp1 a highly durable protection after single intramuscular vaccination. These clinically relevant attributes of a successful vaccine, including high stability, dose-sparing potential, and durable efficacy following a single dose, strengthen the rationale for developing HK-fbp1 as a versatile whole-cell antifungal platform.
- Open Access
- 23 October 2026
- Published by Springer Nature in Research Square
Intramuscular immunization with a CpG-adjuvanted Cryptococcus neoformans vaccine induces sterilizing immune protection.
Despite the rising burden of invasive fungal disease, no fungal vaccine is available to use. Cryptococcus neoformans is a fungal pathogen that initiates pulmonary infection and can disseminate to cause fatal meningoencephalitis. We previously identified HK-fbp1, a heat-inactivated C. neoformans mutant strain lacking the F-box protein Fbp1, that confers durable mucosal protection. Here, we combine HK-fbp1 with the type-C CpG adjuvant ODN2395, enabling effective intramuscular immunization to provide sterilizing immune protection against pulmonary challenge, with mostly complete clearance of fungal burden and blockade of extrapulmonary dissemination. Protection correlated with strong recruitment of innate immune cells to the lung and a coordinated CD4⁺ T-cell response. Cryptococcus-specific CD4⁺ T cells produced IFN-γ and IL-17A in lung-draining lymph nodes, whereas muscle-draining nodes exhibited strong IL-2, consistent with coordinated priming and Th1/Th17 effector programming. Protection required IFN-γ, but not other interferons, and persisted in CD4⁺ T-cell- or B-cell-deficient mice, supporting development for immunocompromised hosts. Together, these findings establish CpG-adjuvanted intramuscular HK-fbp1 vaccination as a clinically tractable strategy that can elicit sterilizing antifungal immunity and provide a foundation for advancing HK-fbp1-based antifungal vaccines.
- 23 October 2026
- Published by Springer Nature in Research Square
Open AccessIntramuscular immunization with a CpG-adjuvanted Cryptococcus neoformans vaccine induces sterilizing immune protection.
Despite the rising burden of invasive fungal disease, no fungal vaccine is available to use. Cryptococcus neoformans is a fungal pathogen that initiates pulmonary infection and can disseminate to cause fatal meningoencephalitis. We previously identified HK-fbp1, a heat-inactivated C. neoformans mutant strain lacking the F-box protein Fbp1, that confers durable mucosal protection. Here, we combine HK-fbp1 with the type-C CpG adjuvant ODN2395, enabling effective intramuscular immunization to provide sterilizing immune protection against pulmonary challenge, with mostly complete clearance of fungal burden and blockade of extrapulmonary dissemination. Protection correlated with strong recruitment of innate immune cells to the lung and a coordinated CD4⁺ T-cell response. Cryptococcus-specific CD4⁺ T cells produced IFN-γ and IL-17A in lung-draining lymph nodes, whereas muscle-draining nodes exhibited strong IL-2, consistent with coordinated priming and Th1/Th17 effector programming. Protection required IFN-γ, but not other interferons, and persisted in CD4⁺ T-cell- or B-cell-deficient mice, supporting development for immunocompromised hosts. Together, these findings establish CpG-adjuvanted intramuscular HK-fbp1 vaccination as a clinically tractable strategy that can elicit sterilizing antifungal immunity and provide a foundation for advancing HK-fbp1-based antifungal vaccines.
- Open Access
- 13 October 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (10)
Interferon crosstalk at the lung barrier in viral and fungal infection
Interferons (IFNs) coordinate host defense at the lung barrier by linking pathogen recognition to epithelial and immune-cell responses. Their effects are highly context-dependent and can be protective or pathological according to IFN class and ligand, cellular source and target, and the timing and duration of signaling. In this minireview, we compare the induction of type I, II, and III IFNs during respiratory viral infection and pulmonary Aspergillus fumigatus infection, highlighting epithelial-led antiviral sensing and predominantly myeloid-centered antifungal sensing. We then examine how receptor distribution, ligand identity, JAK-STAT complex assembly, and integration with inflammatory pathways generate cell type-specific transcriptional and functional programs. Finally, we discuss three interconnected consequences of IFN crosstalk at the respiratory barrier: regulation of epithelial permeability and repair, licensing or pathological reprogramming of immune effector cells during primary infection, and loss of coordination during viral-fungal coinfection, including influenza-associated and COVID-19-associated pulmonary aspergillosis. Collectively, the available evidence supports a model in which spatially restricted and appropriately timed IFN responses promote pathogen control and preserve barrier function, whereas excessive, prolonged, or mistimed signaling impairs epithelial recovery, disrupts phagocyte activity, and increases susceptibility to secondary fungal invasion. Defining these context-dependent circuits may guide therapeutic strategies that modulate IFN signaling with greater temporal and cell type specificity.
- 13 October 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (10)
Open AccessInterferon crosstalk at the lung barrier in viral and fungal infection
Interferons (IFNs) coordinate host defense at the lung barrier by linking pathogen recognition to epithelial and immune-cell responses. Their effects are highly context-dependent and can be protective or pathological according to IFN class and ligand, cellular source and target, and the timing and duration of signaling. In this minireview, we compare the induction of type I, II, and III IFNs during respiratory viral infection and pulmonary Aspergillus fumigatus infection, highlighting epithelial-led antiviral sensing and predominantly myeloid-centered antifungal sensing. We then examine how receptor distribution, ligand identity, JAK-STAT complex assembly, and integration with inflammatory pathways generate cell type-specific transcriptional and functional programs. Finally, we discuss three interconnected consequences of IFN crosstalk at the respiratory barrier: regulation of epithelial permeability and repair, licensing or pathological reprogramming of immune effector cells during primary infection, and loss of coordination during viral-fungal coinfection, including influenza-associated and COVID-19-associated pulmonary aspergillosis. Collectively, the available evidence supports a model in which spatially restricted and appropriately timed IFN responses promote pathogen control and preserve barrier function, whereas excessive, prolonged, or mistimed signaling impairs epithelial recovery, disrupts phagocyte activity, and increases susceptibility to secondary fungal invasion. Defining these context-dependent circuits may guide therapeutic strategies that modulate IFN signaling with greater temporal and cell type specificity.
- Open Access
- 13 January 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (1) , e0035525
Mannoprotein Cig1 contributes to the immunogenicity of a heat-killed F-box protein Fbp1 Cryptococcus neoformans vaccine model
Currently, no fungal vaccine exists for clinical use, while fungal infections are responsible for over 1.5 million deaths every year. Our previous studies identified a Cryptococcus neoformans mutant strain fbp1 Δ as a potential vaccine candidate. This strain contains deletion of the F-box protein Fbp1, a key subunit of the SCF E3 ligase complex necessary for ubiquitin-mediated proteolysis. Vaccination with heat-killed fbp1 Δ (HK- fbp1 ) can elicit an interferon gamma (IFN-γ)-dependent Type 1 immune response and provide protection against C. neoformans and its sibling species C. gattii . However, we have yet to decipher the immunogenic factor(s) expressed by the fbp1 ∆ mutant that are responsible for the induction of the protective immune response. In this study, we have identified that the capsule plays an important role in HK- fbp1 vaccine-mediated protection as acapsular HK- fbp1 cells showed diminished protection against wild-type challenge. Additionally, our studies have shown that Cytokine Inducing Glycoprotein 1 (Cig1), a GPI-anchored mannoprotein, is regulated by Fbp1 and contributes to the immunogenicity of HK- fbp1 . Deletion of Cig1 in the fbp1 Δ background resulted in decreased recruitment of antifungal effector T cells and diminished production of protective inflammatory cytokines by the host. Furthermore, loss of Cig1 in the fbp1 Δ mutant resulted in reduced protection in vaccination survival studies at lower vaccine inoculum doses compared to HK- fbp1 . In aggregate, these findings demonstrate Cig1 is an antigen contributing to the immunogenicity of HK- fbp1 that may be utilized to further optimize the HK- fbp1 fungal vaccine as a tool in the arsenal against invasive fungal infections.
- 13 January 2026
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 94 (1) , e0035525
Open AccessMannoprotein Cig1 contributes to the immunogenicity of a heat-killed F-box protein Fbp1 Cryptococcus neoformans vaccine model
Currently, no fungal vaccine exists for clinical use, while fungal infections are responsible for over 1.5 million deaths every year. Our previous studies identified a Cryptococcus neoformans mutant strain fbp1 Δ as a potential vaccine candidate. This strain contains deletion of the F-box protein Fbp1, a key subunit of the SCF E3 ligase complex necessary for ubiquitin-mediated proteolysis. Vaccination with heat-killed fbp1 Δ (HK- fbp1 ) can elicit an interferon gamma (IFN-γ)-dependent Type 1 immune response and provide protection against C. neoformans and its sibling species C. gattii . However, we have yet to decipher the immunogenic factor(s) expressed by the fbp1 ∆ mutant that are responsible for the induction of the protective immune response. In this study, we have identified that the capsule plays an important role in HK- fbp1 vaccine-mediated protection as acapsular HK- fbp1 cells showed diminished protection against wild-type challenge. Additionally, our studies have shown that Cytokine Inducing Glycoprotein 1 (Cig1), a GPI-anchored mannoprotein, is regulated by Fbp1 and contributes to the immunogenicity of HK- fbp1 . Deletion of Cig1 in the fbp1 Δ background resulted in decreased recruitment of antifungal effector T cells and diminished production of protective inflammatory cytokines by the host. Furthermore, loss of Cig1 in the fbp1 Δ mutant resulted in reduced protection in vaccination survival studies at lower vaccine inoculum doses compared to HK- fbp1 . In aggregate, these findings demonstrate Cig1 is an antigen contributing to the immunogenicity of HK- fbp1 that may be utilized to further optimize the HK- fbp1 fungal vaccine as a tool in the arsenal against invasive fungal infections.
- 10 December 2025
- Published by Elsevier in Cell Host & Microbe
- Vol. 33 (12) , 2007-2009
Hide and seek: Cryptococcus evasion of microglial sensing enables meningitis
- 10 December 2025
- Published by Elsevier in Cell Host & Microbe
- Vol. 33 (12) , 2007-2009
Hide and seek: Cryptococcus evasion of microglial sensing enables meningitis
- 22 August 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (9) , 2106-2108
Mycoviruses steer fungal fitness
- 22 August 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (9) , 2106-2108
Mycoviruses steer fungal fitness
- Open Access
- 5 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
An IFN/STAT1/CYBB axis defines protective plasmacytoid DC–neutrophil crosstalk in Aspergillus fumigatus–infected mice
Aspergillus fumigatus is the most common cause of invasive aspergillosis (IA), a devastating infection in immunocompromised patients. Plasmacytoid DCs (pDCs) regulate host defense against IA by enhancing neutrophil antifungal properties in the lung. Here, we define the pDC activation trajectory during A . fumigatus infection and the molecular events that underlie the protective pDC–neutrophil crosstalk. Fungus-induced pDC activation began after bone marrow egress and resulted in pDC-dependent regulation of lung type I and type III IFN levels. These pDC-derived products acted on type I and type III IFN receptor–expressing neutrophils and controlled neutrophil fungicidal activity and ROS production via STAT1 signaling in a cell-intrinsic manner. Mechanistically, neutrophil STAT1 signaling regulated transcription and expression of Cybb , which encodes one of 5 NADPH oxidase subunits. Thus, the results indicate that pDCs regulate neutrophil-dependent immunity against inhaled molds by controlling local expression of a subunit required for NADPH oxidase assembly and activity in the lung.
- 5 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
Open AccessAn IFN/STAT1/CYBB axis defines protective plasmacytoid DC–neutrophil crosstalk in Aspergillus fumigatus–infected mice
Aspergillus fumigatus is the most common cause of invasive aspergillosis (IA), a devastating infection in immunocompromised patients. Plasmacytoid DCs (pDCs) regulate host defense against IA by enhancing neutrophil antifungal properties in the lung. Here, we define the pDC activation trajectory during A . fumigatus infection and the molecular events that underlie the protective pDC–neutrophil crosstalk. Fungus-induced pDC activation began after bone marrow egress and resulted in pDC-dependent regulation of lung type I and type III IFN levels. These pDC-derived products acted on type I and type III IFN receptor–expressing neutrophils and controlled neutrophil fungicidal activity and ROS production via STAT1 signaling in a cell-intrinsic manner. Mechanistically, neutrophil STAT1 signaling regulated transcription and expression of Cybb , which encodes one of 5 NADPH oxidase subunits. Thus, the results indicate that pDCs regulate neutrophil-dependent immunity against inhaled molds by controlling local expression of a subunit required for NADPH oxidase assembly and activity in the lung.
- Open Access
Mannoprotein Cig1 Contributes to the Immunogenicity of a Heat-Killed F-box Protein Fbp1 Cryptococcus neoformans Vaccine Model
Currently, no fungal vaccine exists for clinical use while fungal infections are responsible for over 1.5 million deaths every year. Our previous studies identified a Cryptococcus neoformans mutant strain fbp1 Δ as a potential vaccine candidate. This mutant strain contains a deletion of the F-box protein Fbp1, a key subunit of the SCF E3 ligase complex necessary for ubiquitin-mediated proteolysis. Vaccination with heat-killed fbp1 Δ (HK- fbp1) can elicit protection against C. neoformans parental strain and its sibling species C. gattii in an interferon gamma (IFN-γ) dependent Type 1 immune response. However, we have yet to decipher the immunogenic factor(s) expressed by the fbp1 Δ mutant that are responsible for the induction of the protective immune response. In this study, we have identified that capsule plays an important role in HK- fbp1 vaccine mediated protection, as acapsular HK- fbp1 cells showed diminished protection against wild type challenge. Additionally, our studies have shown that Cytokine Inducing Glycoprotein 1 (Cig1), a GPI anchored mannoprotein, is regulated by Fbp1 and contributes to the immunogenicity of HK- fbp1 . Deletion of Cig1 in the fbp1 Δ background resulted in decreased recruitment of anti-fungal effector T cells and diminished production of protective inflammatory cytokines by the host. Furthermore, loss of Cig1 in the fbp1 Δ mutant resulted in reduced protection in vaccination survival studies at lower vaccine inoculum doses compared to HK- fbp1 . In aggregate, these findings demonstrate Cig1 is an antigen contributing to the immunogenicity of HK- fbp1 that may be utilized to further optimize the HK- fbp1 fungal vaccine as a tool in the arsenal against invasive fungal infections.
Open AccessMannoprotein Cig1 Contributes to the Immunogenicity of a Heat-Killed F-box Protein Fbp1 Cryptococcus neoformans Vaccine Model
Currently, no fungal vaccine exists for clinical use while fungal infections are responsible for over 1.5 million deaths every year. Our previous studies identified a Cryptococcus neoformans mutant strain fbp1 Δ as a potential vaccine candidate. This mutant strain contains a deletion of the F-box protein Fbp1, a key subunit of the SCF E3 ligase complex necessary for ubiquitin-mediated proteolysis. Vaccination with heat-killed fbp1 Δ (HK- fbp1) can elicit protection against C. neoformans parental strain and its sibling species C. gattii in an interferon gamma (IFN-γ) dependent Type 1 immune response. However, we have yet to decipher the immunogenic factor(s) expressed by the fbp1 Δ mutant that are responsible for the induction of the protective immune response. In this study, we have identified that capsule plays an important role in HK- fbp1 vaccine mediated protection, as acapsular HK- fbp1 cells showed diminished protection against wild type challenge. Additionally, our studies have shown that Cytokine Inducing Glycoprotein 1 (Cig1), a GPI anchored mannoprotein, is regulated by Fbp1 and contributes to the immunogenicity of HK- fbp1 . Deletion of Cig1 in the fbp1 Δ background resulted in decreased recruitment of anti-fungal effector T cells and diminished production of protective inflammatory cytokines by the host. Furthermore, loss of Cig1 in the fbp1 Δ mutant resulted in reduced protection in vaccination survival studies at lower vaccine inoculum doses compared to HK- fbp1 . In aggregate, these findings demonstrate Cig1 is an antigen contributing to the immunogenicity of HK- fbp1 that may be utilized to further optimize the HK- fbp1 fungal vaccine as a tool in the arsenal against invasive fungal infections.
- Top Cited Papers
- 21 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (105) , eadr0547
GM-CSF–mediated epithelial-immune cell cross-talk orchestrates pulmonary immunity to Aspergillus fumigatus
Aspergillus fumigatus causes life-threatening mold pneumonia in immunocompromised patients, particularly in those with quantitative or qualitative defects in neutrophils. Whereas innate immune cell cross-talk licenses neutrophil antifungal activity in the lung, the role of epithelial cells in this process is unknown. Here, we find that surfactant protein C (SPC)–expressing lung epithelial cells integrate infection-induced interleukin-1 and type III interferon signaling to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) preferentially at local sites of fungal infection and neutrophil influx. Using in vivo models that distinguish the role of GM-CSF during acute infection from its homeostatic function in alveolar macrophage survival and surfactant catabolism, we demonstrate that epithelial-derived GM-CSF increases the accumulation and fungicidal activity of GM-CSF–responsive neutrophils, which is essential for host survival. Our findings establish SPC + epithelial cells as a central player in regulating the quality and strength of neutrophil-dependent immunity against inhaled mold pathogens.
- 21 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (105) , eadr0547
Top Cited PapersGM-CSF–mediated epithelial-immune cell cross-talk orchestrates pulmonary immunity to Aspergillus fumigatus
Aspergillus fumigatus causes life-threatening mold pneumonia in immunocompromised patients, particularly in those with quantitative or qualitative defects in neutrophils. Whereas innate immune cell cross-talk licenses neutrophil antifungal activity in the lung, the role of epithelial cells in this process is unknown. Here, we find that surfactant protein C (SPC)–expressing lung epithelial cells integrate infection-induced interleukin-1 and type III interferon signaling to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) preferentially at local sites of fungal infection and neutrophil influx. Using in vivo models that distinguish the role of GM-CSF during acute infection from its homeostatic function in alveolar macrophage survival and surfactant catabolism, we demonstrate that epithelial-derived GM-CSF increases the accumulation and fungicidal activity of GM-CSF–responsive neutrophils, which is essential for host survival. Our findings establish SPC + epithelial cells as a central player in regulating the quality and strength of neutrophil-dependent immunity against inhaled mold pathogens.
- Open Access
- 4 December 2024
- Published by MDPI AG in Journal of Fungi
- Vol. 10 (12) , 840
Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development
Cryptococcus neoformans is an opportunistic fungal pathogen that is a continuous global health concern, especially for immunocompromised populations. The World Health Organization recognized C. neoformans as one of four critical fungal pathogens, thus emphasizing the need for increased research efforts and clinical resource expansion. Currently, there are no fungal vaccines available for clinical use. Exciting new findings in cryptococcal vaccine development have identified whole cell-based and subunit-based vaccinations to help mitigate health risks and make commercialization attainable. Importantly, recent work has focused on how different cryptococcal cell-wall antigens modified in these vaccine candidates allow us to manipulate their immunogenicity to produce a desired long-term protective anti-fungal immune response. In this review, we discuss the different cryptococcal cell immunogens, namely the polysaccharide capsule, glucans, chitin/chitosan, mannoproteins, and extracellular vesicles, and their role in novel cryptococcal vaccination approaches. Additionally, we examine the immunological mechanisms responsible for protection in these vaccine candidates and the similar host response-stimulation pathways induced through different immunogen exposure.
- 4 December 2024
- Published by MDPI AG in Journal of Fungi
- Vol. 10 (12) , 840
Open AccessWill the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development
Cryptococcus neoformans is an opportunistic fungal pathogen that is a continuous global health concern, especially for immunocompromised populations. The World Health Organization recognized C. neoformans as one of four critical fungal pathogens, thus emphasizing the need for increased research efforts and clinical resource expansion. Currently, there are no fungal vaccines available for clinical use. Exciting new findings in cryptococcal vaccine development have identified whole cell-based and subunit-based vaccinations to help mitigate health risks and make commercialization attainable. Importantly, recent work has focused on how different cryptococcal cell-wall antigens modified in these vaccine candidates allow us to manipulate their immunogenicity to produce a desired long-term protective anti-fungal immune response. In this review, we discuss the different cryptococcal cell immunogens, namely the polysaccharide capsule, glucans, chitin/chitosan, mannoproteins, and extracellular vesicles, and their role in novel cryptococcal vaccination approaches. Additionally, we examine the immunological mechanisms responsible for protection in these vaccine candidates and the similar host response-stimulation pathways induced through different immunogen exposure.